NICE Backs Teva’s Ajovy for Migraines

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Teva’s Ajovy (fremanezumab) for preventing migraine.

For chronic migraine, the institute said most likely cost-effectiveness estimates are within the institute’s range of an acceptable use of the National Health Services’ resources, assuming it works better than botulinum type A.

NICE did not recommend the treatment for episodic migraine due to uncertainty about how stopping the treatment and quality of life affect its cost-effectiveness estimates.